CLAIMS

1. Use of *C. difficile* toxoid A and toxiod B in the manufacture of a medicament for eliciting an immune response against *C. difficile* toxin A and toxin B in an adult human subject at risk of a primary symptomatic *C. difficile* infection, the medicament comprising a composition comprising *C. difficile* toxoid A and toxoid B at a purity of 90% or higher (w/w) at an effective toxoid A to toxoid B ratio, and for administration at least three times to the subject, the first and second administrations being five to eight days apart, and wherein the immune response against *C. difficile* toxin A and toxin B is sustained above baseline for at least 210 days.
2. The use of claim 1 wherein the immune response elicited is sufficient to prevent and / or reduce the risk of a primary symptomatic *C. difficile* infection in the adult human subject.
3. The use of claim 1 wherein the immune response elicited is sufficient to prevent the onset of a symptomatic *C. difficile* infection in the adult human subject.
4. The use of any one of claims 1-3 wherein the third administration is 30 days after the first or second administration.
5. The use of any one of claims 1-3 wherein the third administration is 180 days after the first or second administration.
6. The use of claim 5 wherein the third administration is 180 days after the first administration.
7. The use of any one of claims 1-6 wherein the effective ratio is 3:1 to 1:1.
8. The use of claim 7 wherein the ratio of *C. difficile* toxoid A and toxoid B is 3:2.
9. The use of any preceding claim wherein the composition comprises a combined total of *C. difficile* toxoid A and toxoid B of 40 to 500 μg.
10. The use of any preceding claim wherein the composition comprises an adjuvant.
11. The use of claim 10 wherein the composition comprises an aluminum adjuvant.
12. The use of any preceding claim wherein the subject at risk is at least 40 years of age and:

(i) has had, in the 12 month period before the first administration, at least 2 hospital stays, each lasting at least 24 or 72 hours, and has received systemic but not topical antibiotics, or

(ii) is anticipated to have an in-patient hospitalization for a planned surgical procedure within 60 days of the first administration.

13. The use of claim 12, wherein the anticipated hospitalization is planned to be for at least 24 or 72 hours and is for a surgery involving at least one of the following systems: (i) kidney/bladder/urinary system; (ii) musculoskeletal system; (iii) respiratory system; (iv) circulatory system; and (v) central nervous system.

14. The use of any preceding claim wherein the adult human subject is at least 65 years or older.

15. The use of any preceding claim wherein an immune response against *C. difficile* toxin A and / or toxin B is sustained above baseline for at least 1000 days.

16. Use of *C. difficile* toxoid A and toxoid B in the manufacture of a medicament for eliciting an immune response against *C. difficile* toxin A and toxin B in a human subject at risk for a primary symptomatic *C. difficile* infection, the medicament comprising a composition comprising *C. difficile* toxoid A and toxoid B at a purity of 90% or higher (w/w) and for administration at least three times to the subject, the first and second administrations being five to eight days apart, and wherein the immune response against *C. difficile* toxin A and toxin B is sustained above baseline for at least 210 days.